Chugai Seiyaku Kabushiki Kaisha

University College London

Yasuo Koishihara

Masaaki Kosaka

Masayuki Tsuchiya

Toshihiko Ohtomo

Yasushi Yoshimura

Shigeto Kawai

Koichiro Ono

Masahiko Mihara

Shin-ichi Kaiho

Yong Kwee

Shinichiro Iida

Yasuko Ozaki

A cancer vaccine containing as an active ingredient an antigen-specific dendritic cell pulsed by an HM1.24 protein, HM1.24 peptide or transduced with an HM1.24-encoding gene, or HM1.24 protein-encoding DNA or RNA.

HM1.24&#x2014;utilizing cancer vaccines

A therapeutic agent for solid tumors, the agent comprising as an active ingredient, an antibody that specifically binds to a protein having the amino acid sequence represented by SEQ ID NO:2 or an antibody fragment maintaining the antibody activity.

Therapeutic agents for solid tumors

The invention provides a reshaped human anti-HM 1.24 antibody having: (A) an L chain having (1) the C region of a human L chain, and (2) the V region of an L chain having the FR of a human L chain and the CDR of the L chain of a mouse anti-HM 1.24 monoclonal antibody; and (B) an H chain having (1) the C region of a human H chain, and (2) the V region of an H chain having the FR of a human H chain and the CDR of the H chain of a mouse anti-HM 1.24 monoclonal antibody. This reshaped human antibody is derived from human antibody and the CDR has a low antigenicity, and the reshaped human antibody of the present invention has a low antigenicity and can be used for medical treatment.

Reshaped human anti-HM 1.24 antibody

An enhancer, for treatment of lymphocytic tumors, of an antibody that specifically binds to protein having the amino acid sequence as set forth in SEQ ID NO: 1 and that has a cytotoxic activity, said enhancer comprising a biological response modifier as an active ingredient.

Enhancer for antibody to lymphocytic tumors

The present invention is directed to a novel method for quantifying antigen, such as the amount expressed on a cell. The method comprises formulating an equation of correlation between the amount expressed of expressed antigen and the intensity of fluorescence from fluorescent labelled antibody.

Method of quantifying antigen expression

There are provided a genomic DNA comprising 4 exons encoding the amino acid sequence as set forth in SEQ ID NO: 2 and 3 introns ligating them, and a splicing variant of said genomic DNA; as well as a DNA having the base sequence as set forth in SEQ ID NO: 4 and a promoter activity and the fragment thereof, and uses thereof.

Gene encoding HM1.24 antigen protein and promoter thereof

A method of culturing a protein-producing cell, said method comprising co-culturing one transformed cell that can constitutively produce said protein with the parent cell of said transformed cell.

Method of culturing cells

A therapeutic agent for lymphatic tumors (excluding myeloma) comprising as an active ingredient an antibody that specifically binds to a protein having the amino acid sequence as set forth in SEQ ID NO:1 and SEQ ID NO:5 and that has a cytotoxic activity.

Growing community of inventors

Gotenba, Japan

Yasuo Koishihara